CliffBio
small molecule

TOLAZAMIDE

TOLAZAMIDE

Loss of exclusivity—loss of exclusivity
CompanyPar →See this company's full patent-cliff portfolio

Drug detail

Brand nameTOLAZAMIDE
Active ingredientTOLAZAMIDE
Strength100MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 1986
Marketing statusDISCN

More from Par

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TOLAZAMIDE patent cliff — loss of exclusivity — | CliffBio